Show simple item record

dc.contributor.authorGopal, SK
dc.contributor.authorGreening, DW
dc.contributor.authorMathias, RA
dc.contributor.authorJi, H
dc.contributor.authorRai, A
dc.contributor.authorChen, M
dc.contributor.authorZhu, H-J
dc.contributor.authorSimpson, RJ
dc.date.accessioned2020-12-21T02:35:08Z
dc.date.available2020-12-21T02:35:08Z
dc.date.issued2015-05-30
dc.identifierpii: 3764
dc.identifier.citationGopal, S. K., Greening, D. W., Mathias, R. A., Ji, H., Rai, A., Chen, M., Zhu, H. -J. & Simpson, R. J. (2015). YBX1/YB-1 induces partial EMT and tumourigenicity through secretion of angiogenic factors into the extracellular microenvironment. ONCOTARGET, 6 (15), pp.13718-13730. https://doi.org/10.18632/oncotarget.3764.
dc.identifier.issn1949-2553
dc.identifier.urihttp://hdl.handle.net/11343/256986
dc.description.abstractEpithelial-mesenchymal transition (EMT) describes a morphogenetic program which confers mesenchymal cell properties, such as reduced cell-cell contact and increased cell migration and invasion, to epithelial cells. Here we investigate the role of the pleiotropic transcription/splicing factor and RNA-binding protein nuclease-sensitive element-binding protein 1 (YBX1/YB-1) in increasing the oncogenic potential of epithelial MDCK cells. Characterization of MDCK cells expressing YBX1 (MDCKYBX1 cells) revealed a partial EMT phenotype, including cytosolic relocalization of E-cadherin, increased cell scattering, and anchorage-independent growth. Subcutaneous injection of parental MDCK cells into NOD/SCID mice did not form tumours. Critically, MDCKYBX1 cells established viable tumour xenografts, and immuno-histochemical staining indicated murine vascularization by CD31+ endothelial cells. We analysed the total secretome (containing soluble and extracellular vesicles) of MDCKYBX1 cells to investigate regulation of the tumour microenvironment. YBX1 expression elevated release of secreted factors known to enhance angiogenesis (TGF-β, CSF-1, NGF, VGF, ADAM9 and ADAM17), compared to MDCK cells. Importantly, treatment with MDCKYBX1 cell-derived secretome increased recipient 2F-2B endothelial cell motility. This defines YBX1 as an oncogenic enhancer that can regulate tumour angiogenesis via release of secreted modulators into the extracellular microenvironment.
dc.languageEnglish
dc.publisherIMPACT JOURNALS LLC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleYBX1/YB-1 induces partial EMT and tumourigenicity through secretion of angiogenic factors into the extracellular microenvironment
dc.typeJournal Article
dc.identifier.doi10.18632/oncotarget.3764
melbourne.affiliation.departmentSurgery (RMH)
melbourne.source.titleOncotarget
melbourne.source.volume6
melbourne.source.issue15
melbourne.source.pages13718-13730
melbourne.identifier.nhmrc628727
dc.rights.licenseCC BY
melbourne.elementsid1236088
melbourne.contributor.authorZhu, Hongjian
dc.identifier.eissn1949-2553
melbourne.identifier.fundernameidNHMRC, 628727
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record